Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus.

Tytuł:
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus.
Autorzy:
Negrete OA; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, California, USA.
Wolf MC
Aguilar HC
Enterlein S
Wang W
Mühlberger E
Su SV
Bertolotti-Ciarlet A
Flick R
Lee B
Źródło:
PLoS pathogens [PLoS Pathog] 2006 Feb; Vol. 2 (2), pp. e7. Date of Electronic Publication: 2006 Feb 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science, c2005-
MeSH Terms:
Ephrin-B3/*chemistry
Ephrin-B3/*metabolism
Nipah Virus/*metabolism
Receptors, Virus/*metabolism
Animals ; Binding Sites ; CHO Cells ; Cricetinae ; Cricetulus ; Ephrin-B2/genetics ; Ephrin-B2/metabolism ; Ephrin-B3/genetics ; Henipavirus Infections/virology ; Humans ; Leucine ; Nipah Virus/physiology ; Tryptophan
References:
Genes Dev. 2003 Jun 15;17(12):1429-50. (PMID: 12815065)
Antiviral Res. 2003 Jan;57(1-2):113-9. (PMID: 12615307)
J Virol. 2004 Mar;78(5):2597-600. (PMID: 14963164)
IUBMB Life. 2004 May;56(5):257-65. (PMID: 15370889)
Dev Cell. 2004 Oct;7(4):465-80. (PMID: 15469835)
Proc Natl Acad Sci U S A. 1985 May;82(10):3197-201. (PMID: 3858816)
Dev Biol. 1996 Nov 1;179(2):382-401. (PMID: 8903354)
Genomics. 1997 Apr 1;41(1):17-24. (PMID: 9126477)
Oncogene. 1998 Jan 29;16(4):471-80. (PMID: 9484836)
Annu Rev Neurosci. 1998;21:309-45. (PMID: 9530499)
Cell. 1998 May 29;93(5):741-53. (PMID: 9630219)
Exp Neurol. 1999 Mar;156(1):218-22. (PMID: 10192794)
Neuroscience. 1999;91(1):193-201. (PMID: 10336070)
Nature. 1999 Jul 1;400(6739):77-81. (PMID: 10403252)
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. (PMID: 15561600)
Ann N Y Acad Sci. 2004 Oct;1026:1-11. (PMID: 15604464)
J Neuropsychiatry Clin Neurosci. 2004 Fall;16(4):500-4. (PMID: 15616178)
Blood. 2005 Feb 1;105(3):1310-8. (PMID: 15471957)
Emerg Infect Dis. 2004 Dec;10(12):2082-7. (PMID: 15663842)
Physiol Genomics. 2005 Apr 14;21(2):152-60. (PMID: 15671251)
J Immunol. 2005 Jul 1;175(1):413-20. (PMID: 15972675)
Emerg Infect Dis. 2005 Jul;11(7):1042-7. (PMID: 16022778)
Nature. 2005 Jul 21;436(7049):401-5. (PMID: 16007075)
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10652-7. (PMID: 15998730)
Science. 2003 Mar 21;299(5614):1889-92. (PMID: 12649481)
AJNR Am J Neuroradiol. 2000 Mar;21(3):455-61. (PMID: 10730635)
N Engl J Med. 2000 Apr 27;342(17):1229-35. (PMID: 10781618)
J Infect Dis. 2000 May;181(5):1755-9. (PMID: 10823779)
Science. 2000 May 26;288(5470):1432-5. (PMID: 10827955)
Virology. 2000 Jun 5;271(2):334-49. (PMID: 10860887)
Nat Neurosci. 2000 Nov;3(11):1091-7. (PMID: 11036265)
Neuron. 2001 Jan;29(1):85-97. (PMID: 11182083)
Genes Dev. 2001 Apr 1;15(7):877-88. (PMID: 11297511)
Microbes Infect. 2001 Apr;3(4):307-14. (PMID: 11334748)
Microbes Infect. 2001 Apr;3(4):315-22. (PMID: 11334749)
Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85. (PMID: 11750881)
Neuron. 2001 Dec 20;32(6):1027-40. (PMID: 11754835)
Nature. 2001 Dec 20-27;414(6866):933-8. (PMID: 11780069)
Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86. (PMID: 12094214)
J Cell Sci. 2002 Aug 1;115(Pt 15):3073-81. (PMID: 12118063)
Am J Pathol. 2002 Dec;161(6):2153-67. (PMID: 12466131)
J Neurosci Res. 2003 Jan 1;71(1):7-22. (PMID: 12478610)
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):131-3. (PMID: 12486285)
Cell Tissue Res. 2003 Oct;314(1):25-31. (PMID: 12905065)
Grant Information:
AI060694 United States AI NIAID NIH HHS; R01 AI060694 United States AI NIAID NIH HHS; GM07185 United States GM NIGMS NIH HHS; R21 AI059051 United States AI NIAID NIH HHS; T32 AI007323 United States AI NIAID NIH HHS; AI28697 United States AI NIAID NIH HHS; CA16042 United States CA NCI NIH HHS; AI07323 United States AI NIAID NIH HHS; P30 CA016042 United States CA NCI NIH HHS; P30 AI028697 United States AI NIAID NIH HHS; T32 GM007185 United States GM NIGMS NIH HHS; AI059051 United States AI NIAID NIH HHS
Substance Nomenclature:
0 (Ephrin-B2)
0 (Ephrin-B3)
0 (Receptors, Virus)
8DUH1N11BX (Tryptophan)
GMW67QNF9C (Leucine)
Entry Date(s):
Date Created: 20060216 Date Completed: 20060627 Latest Revision: 20181113
Update Code:
20240104
PubMed Central ID:
PMC1361355
DOI:
10.1371/journal.ppat.0020007
PMID:
16477309
Czasopismo naukowe
EphrinB2 was recently discovered as a functional receptor for Nipah virus (NiV), a lethal emerging paramyxovirus. Ephrins constitute a class of homologous ligands for the Eph class of receptor tyrosine kinases and exhibit overlapping expression patterns. Thus, we examined whether other ephrins might serve as alternative receptors for NiV. Here, we show that of all known ephrins (ephrinA1-A5 and ephrinB1-B3), only the soluble Fc-fusion proteins of ephrinB3, in addition to ephrinB2, bound to soluble NiV attachment protein G (NiV-G). Soluble NiV-G bound to cell surface ephrinB3 and B2 with subnanomolar affinities (Kd = 0.58 nM and 0.06 nM for ephrinB3 and B2, respectively). Surface plasmon resonance analysis indicated that the relatively lower affinity of NiV-G for ephrinB3 was largely due to a faster off-rate (K(off) = 1.94 x 10(-3) s(-1) versus 1.06 x 10(-4) s(-1) for ephrinB3 and B2, respectively). EphrinB3 was sufficient to allow for viral entry of both pseudotype and live NiV. Soluble ephrinB2 and B3 were able to compete for NiV-envelope-mediated viral entry on both ephrinB2- and B3-expressing cells, suggesting that NiV-G interacts with both ephrinB2 and B3 via an overlapping site. Mutational analysis indicated that the Leu-Trp residues in the solvent exposed G-H loop of ephrinB2 and B3 were critical determinants of NiV binding and entry. Indeed, replacement of the Tyr-Met residues in the homologous positions in ephrinB1 with Leu-Trp conferred NiV receptor activity to ephrinB1. Thus, ephrinB3 is a bona fide alternate receptor for NiV entry, and two residues in the G-H loop of the ephrin B-class ligands are critical determinants of NiV receptor activity.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies